{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:14:52Z","timestamp":1791274492616,"version":"4.1.0"},"reference-count":180,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIA","award":["RF1 AG072510"],"award-info":[{"award-number":["RF1 AG072510"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common cause of dementia in older adults, marked by a gradual and irreversible deterioration of cognitive abilities, including memory and thinking skills. AD is highly heterogeneous, with variations in amyloid and tau pathology, symptoms, proteostasis, neuroinflammation, and genetics. Dysregulated proteostasis and neuroinflammation, though usually protective, contribute significantly to disease progression. Proteostasis refers to the network that maintains the integrity of both intracellular and extracellular proteins, while neuroinflammation is the biological response to harmful stimuli. Proteostasis stress can activate immune responses and cause excessive inflammation, while impaired microglia and astrocyte function can further disrupt proteostasis and worsen disease progression. While numerous reviews on AD exist, this review focuses on the complex interplay between proteostasis and neuroinflammation in AD and their integral roles in disease pathology. Additionally, we will explore current and promising therapeutics targeting these processes, potential biomarkers, and the clinical trials conducted over the past 5 years, particularly those that address neuroinflammation and proteostasis, as identified through a PubMed search.<\/jats:p>","DOI":"10.31083\/jin39826","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:40:06Z","timestamp":1760157606000},"source":"Crossref","is-referenced-by-count":9,"title":["Proteostasis and Neuroinflammation in Alzheimer\u2019s Disease"],"prefix":"10.31083","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0269-7705","authenticated-orcid":true,"given":"Augustina","family":"Potokiri","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Neuroscience, Garrison Institute on Aging, and Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79430-6592, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-4458","authenticated-orcid":true,"given":"Hongmin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Neuroscience, Garrison Institute on Aging, and Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79430-6592, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, et al. Alzheimer\u2019s Disease: An Update and Insights Into Pathophysiology. Frontiers in Aging Neuroscience. 2022; 14: 742408.","DOI":"10.3389\/fnagi.2022.742408"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"El Kadmiri N, Zaid N, Zaid Y, Tadevosyan A, Hachem A, Dub\u00e9 MP, et al. Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer\u2019s Disease. Neuroscience. 2014; 269: 215\u2013222.","DOI":"10.1016\/j.neuroscience.2014.03.052"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Manola MS, Gumeni S, Trougakos IP. Differential Dose- and Tissue-Dependent Effects of foxo on Aging, Metabolic and Proteostatic Pathways. Cells. 2021; 10: 3577.","DOI":"10.3390\/cells10123577"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Behl C. Biochemistry and Genetics Point Out a Prime Suspect for Causing Alzheimer\u2019s Disease. In Alzheimer\u2019s Disease Research: What Has Guided Research So Far and Why It Is High Time for a Paradigm Shift (pp. 109\u2013117). Springer: Cham. 2023.","DOI":"10.1007\/978-3-031-31570-1_7"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduction and Targeted Therapy. 2023; 8: 248.","DOI":"10.1038\/s41392-023-01484-7"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Rahman MM, Lendel C. Extracellular protein components of amyloid plaques and their roles in Alzheimer\u2019s disease pathology. Molecular Neurodegeneration. 2021; 16: 59.","DOI":"10.1186\/s13024-021-00465-0"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Le Guen Y, Luo G, Ambati A, Damotte V, Jansen I, Yu E, et al. Multiancestry analysis of the HLA locus in Alzheimer\u2019s and Parkinson\u2019s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes. Proceedings of the National Academy of Sciences of the United States of America. 2023; 120: e2302720120.","DOI":"10.1073\/pnas.2302720120"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Pan RY, He L, Zhang J, Liu X, Liao Y, Gao J, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer\u2019s disease. Cell Metabolism. 2022; 34: 634\u2013648.e6.","DOI":"10.1016\/j.cmet.2022.02.013"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Kalafatakis I, Karagogeos D. Oligodendrocytes and Microglia: Key Players in Myelin Development, Damage and Repair. Biomolecules. 2021; 11: 1058.","DOI":"10.3390\/biom11071058"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hughes AN. Glial Cells Promote Myelin Formation and Elimination. Frontiers in Cell and Developmental Biology. 2021; 9: 661486.","DOI":"10.3389\/fcell.2021.661486"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Unger MS, Schernthaner P, Marschallinger J, Mrowetz H, Aigner L. Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. Journal of Neuroinflammation. 2018; 15: 274.","DOI":"10.1186\/s12974-018-1304-4"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Cai Y, Liu J, Wang B, Sun M, Yang H. Microglia in the Neuroinflammatory Pathogenesis of Alzheimer\u2019s Disease and Related Therapeutic Targets. Frontiers in Immunology. 2022; 13: 856376.","DOI":"10.3389\/fimmu.2022.856376"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Twarowski B, Herbet M. Inflammatory Processes in Alzheimer\u2019s Disease-Pathomechanism, Diagnosis and Treatment: A Review. International Journal of Molecular Sciences. 2023; 24: 6518.","DOI":"10.3390\/ijms24076518"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Weng Y, Xie G. Increased GABBR2 Expression on Cell Membranes Causes Increased Ca2 + Inward Flow, Associated with Cognitive Impairment in Early Alzheimer\u2019s Disease. Biochemical Genetics. 2024.  (online ahead of print)","DOI":"10.1007\/s10528-024-11004-z"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Zu HB, Liu XY, Yao K. DHCR24 overexpression modulates microglia polarization and inflammatory response via Akt\/GSK3\u03b2 signaling in A\u03b225-35 treated BV-2 cells. Life Sciences. 2020; 260: 118470.","DOI":"10.1016\/j.lfs.2020.118470"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Tecalco-Cruz AC, Pedraza-Chaverri J, Briones-Herrera A, Cruz-Ramos E, L\u00f3pez-Canovas L, Zepeda-Cervantes J. Protein degradation-associated mechanisms that are affected in Alzheimer\u00b4s disease. Molecular and Cellular Biochemistry. 2022; 477: 915\u2013925.","DOI":"10.1007\/s11010-021-04334-8"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Schmidt MF, Gan ZY, Komander D, Dewson G. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. Cell Death and Differentiation. 2021; 28: 570\u2013590.","DOI":"10.1038\/s41418-020-00706-7"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhang W, Xu C, Sun J, Shen HM, Wang J, Yang C. Impairment of the autophagy-lysosomal pathway in Alzheimer\u2019s diseases: Pathogenic mechanisms and therapeutic potential. Acta Pharmaceutica Sinica. B. 2022; 12: 1019\u20131040.","DOI":"10.1016\/j.apsb.2022.01.008"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Zhong G, Fang Z, Sun T, Ying M, Wang A, Chen Y, et al. Ubiquitin ligase RFWD2 promotes dendritic spine and synapse formation by activating the ERK\/PEA3\/c-Jun pathway in rat cerebral cortical neurons. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2024; 1870: 167319.","DOI":"10.1016\/j.bbadis.2024.167319"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Deleyto-Seldas N, Efeyan A. The mTOR-Autophagy Axis and the Control of Metabolism. Frontiers in Cell and Developmental Biology. 2021; 9: 655731.","DOI":"10.3389\/fcell.2021.655731"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Zhao X, Yang J. Amyloid-\u03b2 peptide is a substrate of the human 20S proteasome. ACS Chemical Neuroscience. 2010; 1: 655\u2013660.","DOI":"10.1021\/cn100067e"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Hipp MS, Hartl FU. Interplay of Proteostasis Capacity and Protein Aggregation: Implications for Cellular Function and Disease. Journal of Molecular Biology. 2024; 436: 168615.","DOI":"10.1016\/j.jmb.2024.168615"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Mayor A, Martinon F, De Smedt T, P\u00e9trilli V, Tschopp J. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nature Immunology. 2007; 8: 497\u2013503.","DOI":"10.1038\/ni1459"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhang YH, Guo C, Gao HL, Zhong ML, Huang TT, et al. Tetrathiomolybdate Treatment Leads to the Suppression of Inflammatory Responses through the TRAF6\/NF\u03baB Pathway in LPS-Stimulated BV-2 Microglia. Frontiers in Aging Neuroscience. 2018; 10: 9.","DOI":"10.3389\/fnagi.2018.00009"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"\u00c7etin G, Studencka-Turski M, Venz S, Schormann E, Junker H, Hammer E, et al. Immunoproteasomes control activation of innate immune signaling and microglial function. Frontiers in Immunology. 2022; 13: 982786.","DOI":"10.3389\/fimmu.2022.982786"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Bai Y, Ma X. Chlorzoxazone exhibits neuroprotection against Alzheimer\u2019s disease by attenuating neuroinflammation and neurodegeneration in vitro and in vivo. International Immunopharmacology. 2020; 88: 106790.","DOI":"10.1016\/j.intimp.2020.106790"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH. Neuroinflammation in Alzheimer\u2019s Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation. 2023; 46: 1\u201317.","DOI":"10.1007\/s10753-022-01721-1"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Paolicelli RC, Sierra A, Stevens B, Tremblay ME, Aguzzi A, Ajami B, et al. Microglia states and nomenclature: A field at its crossroads. Neuron. 2022; 110: 3458\u20133483.","DOI":"10.1016\/j.neuron.2022.10.020"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Fumagalli L, Nazlie Mohebiany A, Premereur J, Polanco Miquel P, Bijnens B, Van de Walle P, et al. Microglia heterogeneity, modeling and cell-state annotation in development and neurodegeneration. Nature Neuroscience. 2025.  (online ahead of print)","DOI":"10.1038\/s41593-025-01931-4"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Li D, Cui YL, Li H, Huang SL, Fan Y. Resveratrol attenuates inflammation by regulating macrophage polarization via inhibition of toll-like receptor 4\/MyD88 signaling pathway. Pharmacognosy Magazine. 2021; 17: 321\u2013326.","DOI":"10.4103\/pm.pm_312_20"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Malayil R, Chhichholiya Y, Vasudeva K, Singh HV, Singh T, Singh S, et al. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes. Medical Oncology (Northwood, London, England). 2023; 40: 174.","DOI":"10.1007\/s12032-023-02037-2"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Dhapola R, Hota SS, Sarma P, Bhattacharyya A, Medhi B, Reddy DH. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer\u2019s disease. Inflammopharmacology. 2021; 29: 1669\u20131681.","DOI":"10.1007\/s10787-021-00889-6"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Yeung YT, Aziz F, Guerrero-Castilla A, Arguelles S. Signaling Pathways in Inflammation and Anti-inflammatory Therapies. Current Pharmaceutical Design. 2018; 24: 1449\u20131484.","DOI":"10.2174\/1381612824666180327165604"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Lashgari NA, Roudsari NM, Shamsnia HS, Shayan M, Momtaz S, Abdolghaffari AH. TLR\/mTOR inflammatory signaling pathway: novel insight for the treatment of schizophrenia. Canadian Journal of Physiology and Pharmacology. 2024; 102: 150\u2013160.","DOI":"10.1139\/cjpp-2023-0107"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Ebrahimi F, Koch M, Pieroh P, Ghadban C, Hobusch C, Bechmann I, et al. Time dependent neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation. Journal of Neuroinflammation. 2012; 9: 89.","DOI":"10.1186\/1742-2094-9-89"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer\u2019s disease: peripheral inflammation or signals from the brain? Journal of Neuroimmunology. 2000; 103: 97\u2013102.","DOI":"10.1016\/s0165-5728(99)00226-x"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Kumari S, Dhapola R, Sharma P, Singh SK, Reddy DH. Implicative role of Cytokines in Neuroinflammation mediated AD and associated signaling pathways: Current Progress in molecular signaling and therapeutics. Ageing Research Reviews. 2023; 102098.","DOI":"10.1016\/j.arr.2023.102098"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Lee CYD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. Journal of Neural Transmission (Vienna, Austria: 1996). 2010; 117: 949\u2013960.","DOI":"10.1007\/s00702-010-0433-4"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Ji YF, Wang YJ, Chen SH, Cheng Y. Interleukin-4 promotes the clearance of amyloid-\u03b2 by monocyte through enhancing the recognition and intracellular processing of amyloid-\u03b2. Journal of Alzheimer\u2019s Disease: JAD. 2024; 102: 1017\u20131026.","DOI":"10.1177\/13872877241295361"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Zuroff LR, Torbati T, Hart NJ, Fuchs DT, Sheyn J, Rentsendorj A, et al. Effects of IL-34 on Macrophage Immunological Profile in Response to Alzheimer\u2019s-Related A\u03b242 Assemblies. Frontiers in Immunology. 2020; 11: 1449.","DOI":"10.3389\/fimmu.2020.01449"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Zhang S, Ye J, Dong G. Neuroprotective effect of baicalein on hydrogen peroxide-mediated oxidative stress and mitochondrial dysfunction in PC12 cells. Journal of Molecular Neuroscience: MN. 2010; 40: 311\u2013320.","DOI":"10.1007\/s12031-009-9285-5"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Ataei S, Abaspanah S, Haddadi R, Mohammadi M, Nili-Ahmadabadi A. Therapeutic Potential of Dihydropyridine Calcium Channel Blockers on Oxidative Injury Caused by Organophosphates in Cortex and Cerebellum: An In Vivo Study. Indian Journal of Clinical Biochemistry: IJCB. 2020; 35: 339\u2013346.","DOI":"10.1007\/s12291-019-00830-3"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Feng Y, Jiang C, Yang F, Chen Z, Li Z. Apocynum venetum leaf extract protects against H2O2-induced oxidative stress by increasing autophagy in PC12 cells. Biomedical Reports. 2020; 13: 6.","DOI":"10.3892\/br.2020.1313"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Lushchak VI. Interplay between bioenergetics and oxidative stress at normal brain aging. Aging as a result of increasing disbalance in the system oxidative stress-energy provision. Pflugers Archiv: European Journal of Physiology. 2021; 473: 713\u2013722.","DOI":"10.1007\/s00424-021-02531-4"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Zu G, Sun K, Li L, Zu X, Han T, Huang H. Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus. Scientific Reports. 2021; 11: 22959.","DOI":"10.1038\/s41598-021-02248-5"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Ulfig A, Jakob U. Cellular oxidants and the proteostasis network: balance between activation and destruction. Trends in Biochemical Sciences. 2024; 49: 761\u2013774.","DOI":"10.1016\/j.tibs.2024.07.001"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Redza-Dutordoir M, Averill-Bates DA. Interactions between reactive oxygen species and autophagy: Special issue: Death mechanisms in cellular homeostasis. Biochimica et Biophysica Acta. Molecular Cell Research. 2021; 1868: 119041.","DOI":"10.1016\/j.bbamcr.2021.119041"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Wang H, Wang A, Wang X, Zeng X, Xing H. AMPK\/PPAR-\u03b3\/NF-\u03baB axis participates in ROS-mediated apoptosis and autophagy caused by cadmium in pig liver. Environmental Pollution (Barking, Essex: 1987). 2022; 294: 118659.","DOI":"10.1016\/j.envpol.2021.118659"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Hetz C. Adapting the proteostasis capacity to sustain brain healthspan. Cell. 2021; 184: 1545\u20131560.","DOI":"10.1016\/j.cell.2021.02.007"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Piccini A, Borghi R, Guglielmotto M, Tamagno E, Cirmena G, Garuti A, et al. \u03b2-amyloid 1-42 induces physiological transcriptional regulation of BACE1. Journal of Neurochemistry. 2012; 122: 1023\u20131031.","DOI":"10.1111\/j.1471-4159.2012.07834.x"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Tamagno E, Guglielmotto M, Monteleone D, Tabaton M. Amyloid-\u03b2 production: major link between oxidative stress and BACE1. Neurotoxicity Research. 2012; 22: 208\u2013219.","DOI":"10.1007\/s12640-011-9283-6"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer\u2019s disease pathogenesis. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2023; 19: 333\u2013342.","DOI":"10.1002\/alz.12683"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Sandberg AA, Manning E, Wilkins HM, Mazzarino R, Minckley T, Swerdlow RH, et al. Mitochondrial Targeting of Amyloid-\u03b2 Protein Precursor Intracellular Domain Induces Hippocampal Cell Death via a Mechanism Distinct from Amyloid-\u03b2. Journal of Alzheimer\u2019s Disease: JAD. 2022; 86: 1727\u20131744.","DOI":"10.3233\/JAD-215108"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Picone P, Nuzzo D, Caruana L, Scafidi V, Di Carlo M. Mitochondrial dysfunction: different routes to Alzheimer\u2019s disease therapy. Oxidative Medicine and Cellular Longevity. 2014; 2014: 780179.","DOI":"10.1155\/2014\/780179"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Olajide OJ, La Rue C, Bergdahl A, Chapman CA. Inhibiting amyloid beta (1-42) peptide-induced mitochondrial dysfunction prevents the degradation of synaptic proteins in the entorhinal cortex. Frontiers in Aging Neuroscience. 2022; 14: 960314.","DOI":"10.3389\/fnagi.2022.960314"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Koopman WJH, Nijtmans LGJ, Dieteren CEJ, Roestenberg P, Valsecchi F, Smeitink JAM, et al. Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation. Antioxidants & Redox Signaling. 2010; 12: 1431\u20131470.","DOI":"10.1089\/ars.2009.2743"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ralph SJ, Moreno-S\u00e1nchez R, Neuzil J, Rodr\u00edguez-Enr\u00edquez S. Inhibitors of succinate: quinone reductase\/Complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death. Pharmaceutical Research. 2011; 28: 2695\u20132730.","DOI":"10.1007\/s11095-011-0566-7"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Cardoso S, Carvalho C, Correia SC, Moreira PI. Protective effects of 2,4-dinitrophenol in okadaic acid-induced cellular model of Alzheimer\u2019s disease. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2024; 1870: 167222.","DOI":"10.1016\/j.bbadis.2024.167222"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Farrugia MY, Caruana M, Ghio S, Camilleri A, Farrugia C, Cauchi RJ, et al. Toxic oligomers of the amyloidogenic HypF-N protein form pores in mitochondrial membranes. Scientific Reports. 2020; 10: 17733.","DOI":"10.1038\/s41598-020-74841-z"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Fernandes T, Resende R, Silva DF, Marques AP, Santos AE, Cardoso SM, et al. Structural and Functional Alterations in Mitochondria-Associated Membranes (MAMs) and in Mitochondria Activate Stress Response Mechanisms in an In Vitro Model of Alzheimer\u2019s Disease. Biomedicines. 2021; 9: 881.","DOI":"10.3390\/biomedicines9080881"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Govindarajulu M, Ramesh S, Beasley M, Lynn G, Wallace C, Labeau S, et al. Role of cGAS-Sting Signaling in Alzheimer\u2019s Disease. International Journal of Molecular Sciences. 2023; 24: 8151.","DOI":"10.3390\/ijms24098151"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Jiang GL, Yang XL, Zhou HJ, Long J, Liu B, Zhang LM, et al. cGAS knockdown promotes microglial M2 polarization to alleviate neuroinflammation by inhibiting cGAS-STING signaling pathway in cerebral ischemic stroke. Brain Research Bulletin. 2021; 171: 183\u2013195.","DOI":"10.1016\/j.brainresbull.2021.03.010"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Quan S, Fu X, Cai H, Ren Z, Xu Y, Jia L. The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer\u2019s disease. Molecular Neurodegeneration. 2025; 20: 25.","DOI":"10.1186\/s13024-025-00815-2"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Alarc\u00f3n-Esp\u00f3sito J, Nagiri RK, Gan L, Sinha SC. Identification and development of cGAS inhibitors and their uses to treat Alzheimer\u2019s disease. Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics. 2025; 22: e00536.","DOI":"10.1016\/j.neurot.2025.e00536"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Huang Y, Liu B, Sinha SC, Amin S, Gan L. Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders. Molecular Neurodegeneration. 2023; 18: 79.","DOI":"10.1186\/s13024-023-00672-x"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Dwamena A, Asadi Y, Gilstrap E, Wang, H. Impaired proteasome induces mitochondrial DNA release to activate the cGAS-STING signaling pathway and cause necroptosis in mouse brain. bioRxiv. 2024.  (preprint)","DOI":"10.1101\/2024.11.13.623442"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Zhang K, Huang Q, Li X, Zhao Z, Hong C, Sun Z, et al. The cGAS-STING pathway in viral infections: a promising link between inflammation, oxidative stress and autophagy. Frontiers in Immunology. 2024; 15: 1352479.","DOI":"10.3389\/fimmu.2024.1352479"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Murthy AMV, Robinson N, Kumar S. Crosstalk between cGAS-STING signaling and cell death. Cell Death and Differentiation. 2020; 27: 2989\u20133003.","DOI":"10.1038\/s41418-020-00624-8"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Liu M, Pan J, Li X, Zhang X, Tian F, Li M, et al. Interleukin-6 deficiency reduces neuroinflammation by inhibiting the STAT3-cGAS-STING pathway in Alzheimer\u2019s disease mice. Journal of Neuroinflammation. 2024; 21: 282.","DOI":"10.1186\/s12974-024-03277-3"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Tawo R, Pokrzywa W, Kevei \u00c9, Akyuz ME, Balaji V, Adrian S, et al. The Ubiquitin Ligase CHIP Integrates Proteostasis and Aging by Regulation of Insulin Receptor Turnover. Cell. 2017; 169: 470\u2013482.e13.","DOI":"10.1016\/j.cell.2017.04.003"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Rebeaud ME, Mallik S, Goloubinoff P, Tawfik DS. On the evolution of chaperones and cochaperones and the expansion of proteomes across the Tree of Life. Proceedings of the National Academy of Sciences of the United States of America. 2021; 118: e2020885118.","DOI":"10.1073\/pnas.2020885118"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Ruan L, Wang Y, Zhang X, Tomaszewski A, McNamara JT, Li R. Mitochondria-Associated Proteostasis. Annual Review of Biophysics. 2020; 49: 41\u201367.","DOI":"10.1146\/annurev-biophys-121219-081604"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Elman JA, Panizzon MS, Gustavson DE, Franz CE, Sanderson-Cimino ME, Lyons MJ, et al. Amyloid-\u03b2 Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-\u03b2 Positivity. Biological Psychiatry. 2020; 87: 819\u2013828.","DOI":"10.1016\/j.biopsych.2019.12.021"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Jayaraj GG, Hipp MS, Hartl FU. Functional Modules of the Proteostasis Network. Cold Spring Harbor Perspectives in Biology. 2020; 12: a033951.","DOI":"10.1101\/cshperspect.a033951"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Calabrese V, Cornelius C, Stella AMG, Calabrese EJ. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. Neurochemical Research. 2010; 35: 1880\u20131915.","DOI":"10.1007\/s11064-010-0307-z"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Nedelsky NB, Todd PK, Taylor JP. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochimica et Biophysica Acta. 2008; 1782: 691\u2013699.","DOI":"10.1016\/j.bbadis.2008.10.002"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Weinberg J, Gaur M, Swaroop A, Taylor A. Proteostasis in aging-associated ocular disease. Molecular Aspects of Medicine. 2022; 88: 101157.","DOI":"10.1016\/j.mam.2022.101157"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Maldonado E, Morales-Pison S, Urbina F, Solari A. Aging Hallmarks and the Role of Oxidative Stress. Antioxidants (Basel, Switzerland). 2023; 12: 651.","DOI":"10.3390\/antiox12030651"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Meyer-Schwesinger C. The ubiquitin-proteasome system in kidney physiology and disease. Nature Reviews. Nephrology. 2019; 15: 393\u2013411.","DOI":"10.1038\/s41581-019-0148-1"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Riederer BM, Leuba G, Vernay A, Riederer IM. The role of the ubiquitin proteasome system in Alzheimer\u2019s disease. Experimental Biology and Medicine (Maywood, N.J.). 2011; 236: 268\u2013276.","DOI":"10.1258\/ebm.2010.010327"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Blasiak J, Pawlowska E, Szczepanska J, Kaarniranta K. Interplay between Autophagy and the Ubiquitin-Proteasome System and Its Role in the Pathogenesis of Age-Related Macular Degeneration. International Journal of Molecular Sciences. 2019; 20: 210.","DOI":"10.3390\/ijms20010210"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Dagar G, Kumar R, Yadav KK, Singh M, Pandita TK. Ubiquitination and deubiquitination: Implications on cancer therapy. Biochimica et Biophysica Acta. Gene Regulatory Mechanisms. 2023; 1866: 194979.","DOI":"10.1016\/j.bbagrm.2023.194979"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Collins GA, Goldberg AL. The Logic of the 26S Proteasome. Cell. 2017; 169: 792\u2013806.","DOI":"10.1016\/j.cell.2017.04.023"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature Reviews. Drug Discovery. 2011; 10: 29\u201346.","DOI":"10.1038\/nrd3321"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Sahu I, Glickman MH. Structural Insights into Substrate Recognition and Processing by the 20S Proteasome. Biomolecules. 2021; 11: 148.","DOI":"10.3390\/biom11020148"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Zhang JY, Liu SJ, Li HL, Wang JZ. Microtubule-associated protein tau is a substrate of ATP\/Mg(2+)-dependent proteasome protease system. Journal of Neural Transmission (Vienna, Austria: 1996). 2005; 112: 547\u2013555.","DOI":"10.1007\/s00702-004-0196-x"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Lehotzky A, Ol\u00e1h J, Fekete JT, Sz\u00e9n\u00e1si T, Szab\u00f3 E, Gy\u0151rffy B, et al. Co-Transmission of Alpha-Synuclein and TPPP\/p25 Inhibits Their Proteolytic Degradation in Human Cell Models. Frontiers in Molecular Biosciences. 2021; 8: 666026.","DOI":"10.3389\/fmolb.2021.666026"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Filimonenko M, Isakson P, Finley KD, Anderson M, Jeong H, Melia TJ, et al. The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy. Molecular Cell. 2010; 38: 265\u2013279.","DOI":"10.1016\/j.molcel.2010.04.007"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Uddin MS, Stachowiak A, Mamun AA, Tzvetkov NT, Takeda S, Atanasov AG, et al. Autophagy and Alzheimer\u2019s Disease: From Molecular Mechanisms to Therapeutic Implications. Frontiers in Aging Neuroscience. 2018; 10: 04.","DOI":"10.3389\/fnagi.2018.00004"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Zhao Y, Xie YZ, Liu YS. Accelerated aging-related transcriptome alterations in neurovascular unit cells in the brain of Alzheimer\u2019s disease. Frontiers in Aging Neuroscience. 2022; 14: 949074.","DOI":"10.3389\/fnagi.2022.949074"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Xia X, Wei Y, Huang Q, Zhou Y, Wang X, Shi Y, et al. Counteracting Alzheimer\u2019s disease via normalizing neurovascular unit with a self-regulated multi-functional nano-modulator. Acta Pharmaceutica Sinica. B. 2024; 14: 5464\u20135478.","DOI":"10.1016\/j.apsb.2024.05.017"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Wang N, Tan Y, Zhou Q, Mao R, Yang Y. The impairment of the hippocampal neuro-vascular unit precedes changes in spatial cognition in naturally aged rats. Neuroscience Letters. 2022; 776: 136580.","DOI":"10.1016\/j.neulet.2022.136580"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Zhong J, Wang L, Li Y, Jiang J. A Novel Diffusion Tensor Image Analysis Along the Perivascular Space Method to Evaluate Glymphatic Alterations in Alzheimer\u2019s Disease. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference. 2023; 2023: 1\u20134.","DOI":"10.1109\/EMBC40787.2023.10340315"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Zhang X, Wang Y, Jiao B, Wang Z, Shi J, Zhang Y, et al. Glymphatic system impairment in Alzheimer\u2019s disease: associations with perivascular space volume and cognitive function. European Radiology. 2024; 34: 1314\u20131323.","DOI":"10.1007\/s00330-023-10122-3"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Zhang X, Cao R, Zhu C, Yang L, Zheng N, Ji W, et al. Mechanism of anti-AD action of OAB-14 by enhancing the function of glymphatic system. Neurochemistry International. 2023; 105633.","DOI":"10.1016\/j.neuint.2023.105633"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Zhang ZY, Harischandra DS, Wang R, Ghaisas S, Zhao JY, McMonagle TP, et al. TRIM11 protects against tauopathies and is down-regulated in Alzheimer\u2019s disease. Science (New York, N.Y.). 2023; 381: eadd6696.","DOI":"10.1126\/science.add6696"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"d\u2019Errico P, Ziegler-Waldkirch S, Aires V, Hoffmann P, Mez\u00f6 C, Erny D, et al. Microglia contribute to the propagation of A\u03b2 into unaffected brain tissue. Nature Neuroscience. 2022; 25: 20\u201325.","DOI":"10.1038\/s41593-021-00951-0"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Pooler AM, Polydoro M, Wegmann S, Nicholls SB, Spires-Jones TL, Hyman BT. Propagation of tau pathology in Alzheimer\u2019s disease: identification of novel therapeutic targets. Alzheimer\u2019s Research & Therapy. 2013; 5: 49.","DOI":"10.1186\/alzrt214"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Ruan Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, Muraoka S, Bhatt N, et al. Alzheimer\u2019s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain: a Journal of Neurology. 2021; 144: 288\u2013309.","DOI":"10.1093\/brain\/awaa376"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Anand C, Maia PD, Torok J, Mezias C, Raj A. The effects of microglia on tauopathy progression can be quantified using Nexopathy in silico (Nexis) models. Scientific Reports. 2022; 12: 21170.","DOI":"10.1038\/s41598-022-25131-3"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Odfalk KF, Bieniek KF, Hopp SC. Microglia: Friend and foe in tauopathy. Progress in Neurobiology. 2022; 216: 102306.","DOI":"10.1016\/j.pneurobio.2022.102306"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nature Reviews. Neuroscience. 2018; 19: 610\u2013621.","DOI":"10.1038\/s41583-018-0055-7"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nature Reviews. Immunology. 2016; 16: 407\u2013420.","DOI":"10.1038\/nri.2016.58"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Li Y, Huang H, Liu B, Zhang Y, Pan X, Yu XY, et al. Inflammasomes as therapeutic targets in human diseases. Signal Transduction and Targeted Therapy. 2021; 6: 247.","DOI":"10.1038\/s41392-021-00650-z"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Gustin A, Kirchmeyer M, Koncina E, Felten P, Losciuto S, Heurtaux T, et al. NLRP3 Inflammasome Is Expressed and Functional in Mouse Brain Microglia but Not in Astrocytes. PloS One. 2015; 10: e0130624.","DOI":"10.1371\/journal.pone.0130624"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Dou RX, Zhang YM, Hu XJ, Gao FL, Zhang LL, Liang YH, et al. A\u03b21-42 promotes microglial activation and apoptosis in the progression of AD by binding to TLR4. Redox Biology. 2024; 78: 103428.","DOI":"10.1016\/j.redox.2024.103428"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Zhang YJ, Guo WJ, Tang ZY, Lin HB, Hong P, Wang JW, et al. Isoflurane Attenuates Cerebral Ischaemia-Reperfusion Injury via the TLR4-NLRP3 Signalling Pathway in Diabetic Mice. Oxidative Medicine and Cellular Longevity. 2022; 2022: 2650693.","DOI":"10.1155\/2022\/2650693"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Liang T, Zhang Y, Wu S, Chen Q, Wang L. The Role of NLRP3 Inflammasome in Alzheimer\u2019s Disease and Potential Therapeutic Targets. Frontiers in Pharmacology. 2022; 13: 845185.","DOI":"10.3389\/fphar.2022.845185"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Johnson NH, Kerr NA, de Rivero Vaccari JP, Bramlett HM, Keane RW, Dietrich WD. Genetic predisposition to Alzheimer\u2019s disease alters inflammasome activity after traumatic brain injury. Translational Research: the Journal of Laboratory and Clinical Medicine. 2023; 257: 66\u201377.","DOI":"10.1016\/j.trsl.2023.02.001"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Zhu MJ, Zhang L, Wang CP. Copper Overload Promotes \u03b2-amyloid Induced NLRP3\/Caspase-1\/GSDMD-Mediated Pyroptosis in Alzheimer\u2019s Disease. Journal of Integrative Neuroscience. 2024; 23: 194.","DOI":"10.31083\/j.jin2310194"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Singh D. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer\u2019s disease. Journal of Neuroinflammation. 2022; 19: 206.","DOI":"10.1186\/s12974-022-02565-0"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Rotondo JC, Mazziotta C, Lanzillotti C, Stefani C, Badiale G, Campione G, et al. The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications. Cancers. 2022; 14: 1116.","DOI":"10.3390\/cancers14051116"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Janks L, Sharma CVR, Egan TM. A central role for P2X7 receptors in human microglia. Journal of Neuroinflammation. 2018; 15: 325.","DOI":"10.1186\/s12974-018-1353-8"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Lester SN, Li K. Toll-like receptors in antiviral innate immunity. Journal of Molecular Biology. 2014; 426: 1246\u20131264.","DOI":"10.1016\/j.jmb.2013.11.024"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes and Infection. 2004; 6: 1382\u20131387.","DOI":"10.1016\/j.micinf.2004.08.018"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Perluigi M, Di Domenico F, Giorgi A, Schinin\u00e0 ME, Coccia R, Cini C, et al. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. Journal of Neuroscience Research. 2010; 88: 3498\u20133507.","DOI":"10.1002\/jnr.22500"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, et al. TREM2 Is a Receptor for \u03b2-Amyloid that Mediates Microglial Function. Neuron. 2018; 97: 1023\u20131031.e7.","DOI":"10.1016\/j.neuron.2018.01.031"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Walter J. The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. The Journal of Biological Chemistry. 2016; 291: 4334\u20134341.","DOI":"10.1074\/jbc.R115.704981"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal \u03b2-catenin pathway function in an Alzheimer\u2019s disease model. Journal of Immunology (Baltimore, Md.: 1950). 2011; 187: 6539\u20136549.","DOI":"10.4049\/jimmunol.1100620"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Chen Y, Yu Y. Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. Journal of Neuroinflammation. 2023; 20: 165.","DOI":"10.1186\/s12974-023-02853-3"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Almalki WH, Almujri SS. Therapeutic approaches to microglial dysfunction in Alzheimer\u2019s disease: Enhancing phagocytosis and metabolic regulation. Pathology, Research and Practice. 2024; 263: 155614.","DOI":"10.1016\/j.prp.2024.155614"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Xu Y, Propson NE, Du S, Xiong W, Zheng H. Autophagy deficiency modulates microglial lipid homeostasis and aggravates tau pathology and spreading. Proceedings of the National Academy of Sciences of the United States of America. 2021; 118: e2023418118.","DOI":"10.1073\/pnas.2023418118"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Ebrahimi T, Rust M, Kaiser SN, Slowik A, Beyer C, Koczulla AR, et al. \u03b11-antitrypsin mitigates NLRP3-inflammasome activation in amyloid \u03b21-42-stimulated murine astrocytes. Journal of Neuroinflammation. 2018; 15: 282.","DOI":"10.1186\/s12974-018-1319-x"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Zou C, Shi Y, Ohli J, Sch\u00fcller U, Dorostkar MM, Herms J. Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer\u2019s disease. Acta Neuropathologica. 2016; 131: 235\u2013246.","DOI":"10.1007\/s00401-015-1527-8"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Zy\u015bk M, Beretta C, Naia L, Dakhel A, P\u00e5v\u00e9nius L, Brismar H, et al. Amyloid-\u03b2 accumulation in human astrocytes induces mitochondrial disruption and changed energy metabolism. Journal of Neuroinflammation. 2023; 20: 43.","DOI":"10.1186\/s12974-023-02722-z"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Verkhratsky A, Parpura V, Rodriguez-Arellano JJ, Zorec R. Astroglia in Alzheimer\u2019s Disease. Advances in Experimental Medicine and Biology. 2019; 1175: 273\u2013324.","DOI":"10.1007\/978-981-13-9913-8_11"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"Kumar A, Fontana IC, Nordberg A. Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer\u2019s disease. Journal of Neurochemistry. 2023; 164: 309\u2013324.","DOI":"10.1111\/jnc.15565"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational Neurodegeneration. 2020; 9: 42.","DOI":"10.1186\/s40035-020-00221-2"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Pal A, Rani I, Pawar A, Picozza M, Rongioletti M, Squitti R. Microglia and Astrocytes in Alzheimer\u2019s Disease in the Context of the Aberrant Copper Homeostasis Hypothesis. Biomolecules. 2021; 11: 1598.","DOI":"10.3390\/biom11111598"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"Fakhoury M. Microglia and Astrocytes in Alzheimer\u2019s Disease: Implications for Therapy. Current Neuropharmacology. 2018; 16: 508\u2013518.","DOI":"10.2174\/1570159X15666170720095240"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Johnstone M, Gearing AJ, Miller KM. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. Journal of Neuroimmunology. 1999; 93: 182\u2013193.","DOI":"10.1016\/s0165-5728(98)00226-4"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Chen Y, Fu AKY, Ip NY. Synaptic dysfunction in Alzheimer\u2019s disease: Mechanisms and therapeutic strategies. Pharmacology & Therapeutics. 2019; 195: 186\u2013198.","DOI":"10.1016\/j.pharmthera.2018.11.006"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer\u2019s Disease. Current Neuropharmacology. 2020; 18: 1106\u20131125.","DOI":"10.2174\/1570159X18666200528142429"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO. Oral Tau Aggregation Inhibitor for Alzheimer\u2019s Disease: Design, Progress and Basis for Selection of the 16 mg\/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. The Journal of Prevention of Alzheimer\u2019s Disease. 2022; 9: 780\u2013790.","DOI":"10.14283\/jpad.2022.63"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Santos RX, Lee SH, Lofthouse R, Melis V, Robinson L, Leith M, et al. Hydromethylthionine sustains truncated tau-dependent inflammation-lowering effects in mouse brain. The FEBS Journal. 2025; 292: 2602\u20132623.","DOI":"10.1111\/febs.70021"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Prins S, de Kam ML, Teunissen CE, Groeneveld GJ. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2022; 14: 106.","DOI":"10.1186\/s13195-022-01051-2"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nature Aging. 2021; 1: 521\u2013534.","DOI":"10.1038\/s43587-021-00070-2"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"Shulman M, Kong J, O\u2019Gorman J, Ratti E, Rajagovindan R, Viollet L, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nature Aging. 2023; 3: 1591\u20131601.","DOI":"10.1038\/s43587-023-00523-w"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, et al. Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer\u2019s disease pathophysiology. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2024; 20: 8855\u20138866.","DOI":"10.1002\/alz.14346"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"Ramakrishnan V, Bender B, Langenhorst J, Magnusson MO, Dolton M, Shim J, et al. Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies. The Journal of Prevention of Alzheimer\u2019s Disease. 2024; 11: 1241\u20131250.","DOI":"10.14283\/jpad.2024.146"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, et al. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet. Neurology. 2023; 101: e1391\u2013e1401.","DOI":"10.1212\/WNL.0000000000207663"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nature Medicine. 2023; 29: 1437\u20131447.","DOI":"10.1038\/s41591-023-02326-3"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"Florian H, Wang D, Arnold SE, Boada M, Guo Q, Jin Z, et al. Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study. Brain: a Journal of Neurology. 2023; 146: 2275\u20132284.","DOI":"10.1093\/brain\/awad024"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, et al. Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer\u2019s Disease. The Journal of Prevention of Alzheimer\u2019s Disease. 2019; 6: 228\u2013231.","DOI":"10.14283\/jpad.2019.37"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P, et al. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2021; 13: 106.","DOI":"10.1186\/s13195-021-00843-2"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimer\u2019s Research & Therapy. 2021; 13: 80.","DOI":"10.1186\/s13195-021-00813-8"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. The New England Journal of Medicine. 2023; 388: 9\u201321.","DOI":"10.1056\/NEJMoa2212948"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Cohen S, van Dyck CH, Gee M, Doherty T, Kanekiyo M, Dhadda S, et al. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer\u2019s Disease. The Journal of Prevention of Alzheimer\u2019s Disease. 2023; 10: 771\u2013777.","DOI":"10.14283\/jpad.2023.123"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330: 512\u2013527.","DOI":"10.1001\/jama.2023.13239"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease. The New England Journal of Medicine. 2023; 389: 1862\u20131876.","DOI":"10.1056\/NEJMoa2304430"},{"key":"ref151","doi-asserted-by":"publisher","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. The Journal of Prevention of Alzheimer\u2019s Disease. 2022; 9: 197\u2013210.","DOI":"10.14283\/jpad.2022.30"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M, et al. Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer\u2019s Disease. The Journal of Prevention of Alzheimer\u2019s Disease. 2024; 11: 1260\u20131269.","DOI":"10.14283\/jpad.2024.106"},{"key":"ref153","doi-asserted-by":"publisher","unstructured":"Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, et al. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer\u2019s disease. Neurobiology of Disease. 2024; 199: 106575.","DOI":"10.1016\/j.nbd.2024.106575"},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, et al. A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter. Translational Neurodegeneration. 2023; 12: 24.","DOI":"10.1186\/s40035-023-00358-w"},{"key":"ref155","doi-asserted-by":"publisher","unstructured":"Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, et al. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer\u2019s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer\u2019s Research & Therapy. 2020; 12: 58.","DOI":"10.1186\/s13195-020-00614-5"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, et al. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2019; 11: 68.","DOI":"10.1186\/s13195-019-0520-1"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"Mirzaei M, Ahmadi N, Bagheri Fahraji B, Ardekani AM, Rahimdel A, Soltani MH, et al. A randomized clinical trial evaluating Hydralazine\u2019s efficacy in early-stage Alzheimer\u2019s disease: The EHSAN Study. Scientific Reports. 2024; 14: 28837.","DOI":"10.1038\/s41598-024-79616-4"},{"key":"ref158","doi-asserted-by":"publisher","unstructured":"Sosa S, Bringas G, Urrutia N, Pe\u00f1alver AI, L\u00f3pez D, Gonz\u00e1lez E, et al. NeuroEPO plus (NeuralCIM\u00ae) in mild-to-moderate Alzheimer\u2019s clinical syndrome: the ATHENEA randomized clinical trial. Alzheimer\u2019s Research & Therapy. 2023; 15: 215.","DOI":"10.1186\/s13195-023-01356-w"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"Hannestad J, Duclos T, Chao W, Koborsi K, Klutzaritz V, Beck B, et al. Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer\u2019s Disease: A Phase II Double-Blind Placebo-Controlled Trial. Journal of Alzheimer\u2019s Disease: JAD. 2021; 81: 1649\u20131662.","DOI":"10.3233\/JAD-210011"},{"key":"ref160","doi-asserted-by":"publisher","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2025; 17: 14.","DOI":"10.1186\/s13195-024-01666-7"},{"key":"ref161","doi-asserted-by":"publisher","unstructured":"Dubois B, L\u00f3pez-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, et al. Masitinib for mild-to-moderate Alzheimer\u2019s disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimer\u2019s Research & Therapy. 2023; 15: 39.","DOI":"10.1186\/s13195-023-01169-x"},{"key":"ref162","doi-asserted-by":"publisher","unstructured":"Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model. The Journal of Experimental Medicine. 2020; 217: e20200785.","DOI":"10.1084\/jem.20200785"},{"key":"ref163","doi-asserted-by":"publisher","unstructured":"Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2024; 16: 235.","DOI":"10.1186\/s13195-024-01599-1"},{"key":"ref164","doi-asserted-by":"publisher","unstructured":"Fang C, Hernandez P, Liow K, Damiano E, Zetterberg H, Blennow K, et al. Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer\u2019s and Parkinson\u2019s Patients. The Journal of Prevention of Alzheimer\u2019s Disease. 2023; 10: 25\u201333.","DOI":"10.14283\/jpad.2022.84"},{"key":"ref165","doi-asserted-by":"publisher","unstructured":"Humpel C. Identifying and validating biomarkers for Alzheimer\u2019s disease. Trends in Biotechnology. 2011; 29: 26\u201332.","DOI":"10.1016\/j.tibtech.2010.09.007"},{"key":"ref166","doi-asserted-by":"publisher","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2018; 14: 1470\u20131481.","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"ref167","doi-asserted-by":"publisher","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. The Lancet. Neurology. 2016; 15: 673\u2013684.","DOI":"10.1016\/S1474-4422(16)00070-3"},{"key":"ref168","doi-asserted-by":"publisher","unstructured":"Taylor J, Jaros M, Chen C, Harrison J, Hilt D. Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11\u03b2-HSD1 Inhibitor Xanamem\u00ae for Mild Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s Disease: JAD. 2024; 100: 139\u2013150.","DOI":"10.3233\/JAD-231456"},{"key":"ref169","doi-asserted-by":"publisher","unstructured":"Lv X, Zhang M, Cheng Z, Wang Q, Wang P, Xie Q, et al. Changes in CSF sPDGFR\u03b2 level and their association with blood-brain barrier breakdown in Alzheimer\u2019s disease with or without small cerebrovascular lesions. Alzheimer\u2019s Research & Therapy. 2023; 15: 51.","DOI":"10.1186\/s13195-023-01199-5"},{"key":"ref170","doi-asserted-by":"publisher","unstructured":"Zhong X, Wang Q, Yang M, Lin G, Yao K, Wu Z, et al. Plasma p-tau217 and p-tau217\/A\u03b21-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2025; 21: e14536.","DOI":"10.1002\/alz.14536"},{"key":"ref171","doi-asserted-by":"publisher","unstructured":"Yakoub Y, Gonzalez-Ortiz F, Ashton NJ, D\u00e9ry C, Strikwerda-Brown C, St-Onge F, et al. Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2025; 21: e14537.","DOI":"10.1002\/alz.14537"},{"key":"ref172","doi-asserted-by":"publisher","unstructured":"Zhuang T, Yang Y, Ren H, Zhang H, Gao C, Chen S, et al. Novel plasma protein biomarkers: A time-dependent predictive model for Alzheimer\u2019s disease. Archives of Gerontology and Geriatrics. 2025; 129: 105650.","DOI":"10.1016\/j.archger.2024.105650"},{"key":"ref173","doi-asserted-by":"publisher","unstructured":"Fotuhi SN, Khalaj-Kondori M, Hoseinpour Feizi MA, Talebi M. Long Non-coding RNA BACE1-AS May Serve as an Alzheimer\u2019s Disease Blood-Based Biomarker. Journal of Molecular Neuroscience: MN. 2019; 69: 351\u2013359.","DOI":"10.1007\/s12031-019-01364-2"},{"key":"ref174","unstructured":"Zhuang J, Cai P, Chen Z, Yang Q, Chen X, Wang X, et al. Long noncoding RNA MALAT1 and its target microRNA-125b are potential biomarkers for Alzheimer\u2019s disease management via interactions with FOXQ1, PTGS2 and CDK5. American Journal of Translational Research. 2020; 12: 5940\u20135954."},{"key":"ref175","doi-asserted-by":"publisher","unstructured":"Zhang T, Kong W, Wang S, Mou X. Association Analysis of Peripheral and CSF Biomarkers in Late Mild Cognitive Impairment. Frontiers in Genetics. 2020; 11: 834.","DOI":"10.3389\/fgene.2020.00834"},{"key":"ref176","doi-asserted-by":"publisher","unstructured":"Rosen KM, Moussa CEH, Lee HK, Kumar P, Kitada T, Qin G, et al. Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function. Journal of Neuroscience Research. 2010; 88: 167\u2013178.","DOI":"10.1002\/jnr.22178"},{"key":"ref177","doi-asserted-by":"publisher","unstructured":"Wojda\u0142a AL, Bellomo G, Gaetani L, Toja A, Chipi E, Shan D, et al. Trajectories of CSF and plasma biomarkers across Alzheimer\u2019s disease continuum: disease staging by NF-L, p-tau181, and GFAP. Neurobiology of Disease. 2023; 189: 106356.","DOI":"10.1016\/j.nbd.2023.106356"},{"key":"ref178","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhao Y, Zhang J, Gao Y, Gao X, Li S, et al. Proteomics of plasma-derived extracellular vesicles reveals S100A8 as a novel biomarker for Alzheimer\u2019s disease: A preliminary study. Journal of Proteomics. 2024; 308: 105279.","DOI":"10.1016\/j.jprot.2024.105279"},{"key":"ref179","doi-asserted-by":"publisher","unstructured":"Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nature Medicine. 2016; 22: 46\u201353.","DOI":"10.1038\/nm.4011"},{"key":"ref180","doi-asserted-by":"publisher","unstructured":"Han X, Sun S, Sun Y, Song Q, Zhu J, Song N, et al. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Autophagy. 2019; 15: 1860\u20131881.","DOI":"10.1080\/15548627.2019.1596481"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/24\/9\/10.31083\/JIN39826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:40:29Z","timestamp":1760157629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/24\/9\/10.31083\/JIN39826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":180,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"alternative-id":["S0219-6352(25)00968-4"],"URL":"https:\/\/doi.org\/10.31083\/jin39826","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"39826"}}